Ionis Pharmaceuticals
Ionis Pharmaceuticals, founded by Stanley T. Crooke, develops RNA-targeted therapeutics and genetic medicines using antisense technology, focusing on rare and common diseases.
Founders
Ionis Pharmaceuticals was founded by Stanley T. Crooke, M.D., Ph.D. Dr. Crooke has been instrumental in establishing the company's focus and vision in the biotechnology sector, particularly in RNA-targeted therapeutics. His leadership and scientific expertise have guided Ionis Pharmaceuticals since its inception.
Services
Ionis Pharmaceuticals develops RNA-targeted therapeutics aimed at addressing a range of medical conditions. Specializing in the discovery, development, and delivery of genetic medicines, Ionis is committed to transforming lives. Their focus includes both rare diseases and more common conditions, leveraging their antisense technology for therapeutic innovation.
Products
Ionis Pharmaceuticals has a diverse pipeline with more than 40 first-in-class and best-in-class medicines. Some of their marketed medicines include SPINRAZA, TEGSEDI, and WAYLIVRA. These products aim to address significant unmet medical needs and showcase Ionis' commitment to advancing genetic medicine.
Sector
Ionis Pharmaceuticals operates within the biotechnology sector, focusing on RNA-targeted therapeutics and genetic medicines. The company specializes in antisense technology, positioning itself at the forefront of genetic medicine development. Their work spans the treatment of rare diseases and conditions affecting larger populations.
History
Since its founding by Stanley T. Crooke, M.D., Ph.D., Ionis Pharmaceuticals has been dedicated to advancing science in the field of genetic medicines. The company's commitment to corporate responsibility and diversity, equity, and inclusion underscores its mission to improve patient lives while maintaining ethical standards.